Abhijit Limaye, MD
Infectious Disease · San Francisco, CANPI 1205972239
Payments from drug & device makers
Across 434 payments — averaging $6766.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$1.3M
- Merck$1.1M
- Roche Molecular Systems, Inc.$258K
- Astellas Pharma Global Development$224K
- GSK$43K
- Novartis Pharma AG$3K
Across 16 payments — averaging $5437.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis Pharma AG$59K
- Novo Nordisk AS$28K
What the payments were for
- Consulting fees$119,26378%
- Travel & lodging$32,27921%
- Food & beverage$6820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 33 | $1,296,491 |
| Merck | 367 | $1,112,216 |
| Roche Molecular Systems, Inc. | 13 | $257,606 |
| Astellas Pharma Global Development | 7 | $224,484 |
| GSK | 13 | $43,292 |
| Novartis Pharma AG | 1 | $2,725 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIN457M_COSENTYX_DERMATOLOGY$2,725
- PREVYMIS$536
How this compares
$2,936,814 in reported general payments places this provider in the 95th percentile of 856 infectious disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ceftazidime | 13 | $2,833 |
| Vancomycin Hcl | 14 | $1,884 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in San Francisco
- Shawn HasslerSan Francisco$4.3M
- Sulggi LeeSan Francisco$1.2M
- Charles ChiuSan Francisco$976K
- Phyllis TienSan Francisco$787K
- Monica FungSan Francisco$683K
- Anne LuetkemeyerSan Francisco$639K
- Monica GandhiSan Francisco$632K
- Catherine KossSan Francisco$530K
- Matthew SpinelliSan Francisco$365K
- Joel PalefskySan Francisco$299K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.